Drug intelligence / Profile preview

SOOPR ES

Development stage: Preclinical
Lead developer: Elysium Therapeutics
Modality: Small Molecules
Administration: Intramuscular, Parenteral

Overview

SOOPR ES is an investigational, extended-protection long-acting injectable opioid antagonist being developed by Elysium Therapeutics. Utilizing the company's proprietary FOLAI (Fast-Onset, Long-Acting Injectable) platform, SOOPR ES is designed to provide rapid-onset and sustained exposure of an opioid antagonist to protect against prolonged or recurrent toxicity from high-potency synthetic opioids (such as fentanyl or nitazenes). The therapy is specifically aimed at operational and mass-casualty settings where repeated monitoring and redosing of short-acting rescue agents (like naloxone) can strain responders and resources. It is currently in preclinical development.

Brand names: SOOPR ES

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on SOOPR ES.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOOPR ES.

Explore the full profile